The FDA has apparently reversed its stance on UniQure's Huntington's gene therapy, with the company now planning to file for approval. However, some reports suggest that regulatory hurdles may still exist, and the therapy's path forward is not entirely clear. The development reflects possible shifts in the FDA's approach to gene therapies, although the specifics and implications of the agency's actions are somewhat uncertain.